Medicine and Dentistry
Patient
100%
Ovarian Cancer
65%
Therapeutic Procedure
50%
Surgery
29%
Woman
26%
Chemotherapy
23%
BRCA1
22%
Recurrent Disease
21%
Cytoreductive Surgery
20%
Diseases
19%
Combination Therapy
18%
Inpatient
16%
Neoplasm
15%
Platinum
14%
Survival
14%
Recurrent Ovarian Cancer
13%
Endometrial Cancer
12%
Progression Free Survival
12%
Neoadjuvant Chemotherapy
12%
Cervical Cancer
11%
Olaparib
10%
PARP Inhibitor
10%
Breast Cancer
10%
Diagnosis
9%
Follow up
9%
Salpingooophorectomy
9%
Malignant Neoplasm
9%
Complication
8%
Overall Survival
8%
Bevacizumab
8%
Krukenberg Tumor
7%
Meta-Analysis
7%
BRCA Mutation
7%
Toxicity
6%
Ovary
6%
Retroperitoneal Lymph Node Dissection
6%
BRCA2
6%
Analysis
6%
Cancer
6%
Paclitaxel
5%
Carboplatin
5%
Vulvar Cancer
5%
Age
5%
Radiation Therapy
5%
Metastatic Carcinoma
5%
Relapse
5%
Pelvis
5%
Cancer Therapy
5%
Female Genital Tract Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
29%
Chemotherapy
23%
Toxicity
10%
Platinum
9%
Paclitaxel
7%
Uterine Cervix Cancer
7%
Diseases
7%
Progression Free Survival
7%
Clinical Trial
6%
Olaparib
6%
Overall Survival
5%
Recurrent Disease
5%
Bevacizumab
5%
